Evaluate Pembrolizumab (Keytruda): CADTH Reimbursement Recommendation: Indicator: Together with chemotherapy, to the remedy of Grownup clients with locally recurrent unresectable or metastatic triple-adverse breast cancer which have not obtained prior chemotherapy for metastatic ailment and whose tumours express programmed mobile Dying-ligand 1 (co